Summary & Overview
HCPCS J9185: Injection, fludarabine phosphate, 50 mg
HCPCS Level II code J9185 designates a 50 mg injection of fludarabine phosphate, an antineoplastic agent used in various hematologic malignancies. Nationally, accurate reporting of this code affects chemotherapy billing, utilization tracking, and payer reimbursement for injectable oncology drugs supplied and administered in outpatient settings. Clarity on coding supports consistent claims adjudication and clinical documentation.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical service associated with J9185, typical sites of service where the injection is billed, and how the code is applied in practice. The publication provides benchmark context for national use, common billing modifiers in scope (listed elsewhere), and implications for claim processing across major commercial and public payers.
This summary equips billing managers, clinical coders, and revenue cycle professionals with the essential facts about the code, what to expect in payer interactions, and the clinical context in which fludarabine phosphate 50 mg is administered. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J9185 represents injection, fludarabine phosphate, 50 mg. This code is used to report administration of the medication fludarabine phosphate in 50 mg increments.
-
Service type: Chemotherapy agent administration (injectable systemic therapy)
-
Typical site of service: Hospital outpatient department, ambulatory infusion center, or physician office infusion suite
Clinical & Coding Specifications
Clinical Context
Medication: J9185 — injection, fludarabine phosphate, 50 mg.
A typical patient is a 62-year-old adult with chronic lymphocytic leukemia (CLL) or low-grade non-Hodgkin lymphoma receiving inpatient or outpatient intravenous chemotherapy. The patient presents to an oncology infusion center or hospital oncology unit after a hematology/oncology clinic visit where fludarabine-based therapy was prescribed as part of single-agent therapy or combination chemotherapy (for example, with cyclophosphamide and rituximab). Prior to infusion, the oncology nurse verifies order accuracy, premedication needs, current labs (complete blood count with differential, creatinine, and liver function tests), and obtains informed consent. Access is established via peripheral IV or implanted port; dose is calculated by weight/body surface area and appropriate dilution and infusion set-up are completed by pharmacy under sterile conditions. During infusion, vital signs and cytopenia risk are monitored; adverse reactions (fever, chills, neurotoxicity, severe myelosuppression) are assessed and documented. Post-infusion, the site documents medication administration, lot number, and any immediate reactions. Billing captures the drug HCPCS code J9185 per 50 mg increment, the appropriate place of service (typically outpatient hospital outpatient department or physician office infusion center), and any applicable modifiers reflecting circumstances of service delivery.
Coding Specifications
| Modifier | Description | When to Use |
|---|